Multiple system atrophy

Common Name(s)

Multiple system atrophy

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by symptoms of autonomic nervous system failure such as fainting spells and bladder control problems, combined with motor control symptoms such as tremor, rigidity, and loss of muscle coordination.  MSA affects both men and women primarily in their 50s.  The disease tends to advance rapidly over the course of 9 to 10 years, with progressive loss of motor skills, eventual confinement to bed, and death. The cause of multiple system atrophy is unknown, although environmental toxins, trauma, and genetic factors have been suggested.  There is no cure for this condition, and there is no known way to prevent the disease from getting worse. The goal of treatment is to control symptoms.  
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Multiple system atrophy" for support, advocacy or research.

Logo
National MSA Support Group

The MSA Support Group has a four pillar mission statement: 1) To support patients and caregivers 2) To educate patients, caregivers, healthcare providers, and others affected by MSA 3) To raise money for MSA research 4) to advocate and create awareness for MSA

Last Updated: 16 Nov 2012

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Multiple system atrophy" for support, advocacy or research.

Logo
National MSA Support Group

The MSA Support Group has a four pillar mission statement: 1) To support patients and caregivers 2) To educate patients, caregivers, healthcare providers, and others affected by MSA 3) To raise money for MSA research 4) to advocate and create awareness for MSA

http://www.shy-drager.org

Last Updated: 16 Nov 2012

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

General Resources

The MSA Research Fund

The MSA Research Fund is the National MSA Support Group's fund dedicated to supporting meaningful MSA research. The Support Group is a 501(c)3 so donations are tax deductible.

Updated 16 Nov 2012

Go To URL
The MSA Forum

The MSA Forum is hosted by the National MSA Support Group. The forum offers an opportunity for patients and caregivers to communicate and share with others affected by MSA.

Updated 16 Nov 2012

Go To URL
 
 
Top

Blogs

The MSA Blog

The multiple system atrophy MSA) blog is dedicated to providing relevant information about support, education, research and advocacy to those affected by MSA

Updated 16 Nov 2012

Go To URL
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Multiple system atrophy" returned 193 free, full-text research articles on human participants. First 3 results:

Mutant COQ2 in multiple-system atrophy.
 

Author(s): Jun Mitsui, Shoji Tsuji

Journal: N. Engl. J. Med.. 2014 Jul;371(1):82-3.

 

Last Updated: 3 Jul 2014

Go To URL
Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.
 

Author(s): Jill S Goldman, Catarina Quinzii, Jane Dunning-Broadbent, Cheryl Waters, Hiroshi Mitsumoto, Thomas H Brannagan, Stephanie Cosentino, Edward D Huey, Peter Nagy, Sheng-Han Kuo

Journal: JAMA Neurol. 2014 Jun;71(6):771-4.

 

Here we report a family with coexistence of multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS) with hexanucleotide repeat expansions in C9orf72.

Last Updated: 10 Jun 2014

Go To URL
Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.
 

Author(s): Phillip A Low, David Robertson, Sid Gilman, Horacio Kaufmann, Wolfgang Singer, Italo Biaggioni, Roy Freeman, Susan Perlman, Robert A Hauser, William Cheshire, Stephanie Lessig, Steven Vernino, Jay Mandrekar, William D Dupont, Thomas Chelimsky, Wendy R Galpern

Journal: Lancet Neurol. 2014 Mar;13(3):268-75.

 

No available treatments slow or halt progression of multiple system atrophy, which is a rare, progressive, fatal neurological disorder. In a mouse model of multiple system atrophy, rifampicin inhibited formation of α-synuclein fibrils, the neuropathological hallmark of the disease. ...

Last Updated: 21 Feb 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Multiple system atrophy" returned 9 free, full-text review articles on human participants. First 3 results:

Multiple system atrophy: a clinical and neuropathological perspective.
 

Author(s): Kiren Ubhi, Phillip Low, Eliezer Masliah

Journal: Trends Neurosci.. 2011 Nov;34(11):581-90.

 

Multiple system atrophy (MSA) is a neurodegenerative disease involving motor abnormalities that include akinesia, rigidity and postural instability. While improved diagnostic criteria have aided the accurate diagnosis of MSA, our understanding of the neuropathological aspects underlying ...

Last Updated: 24 Oct 2011

Go To URL
Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy.
 

Author(s): B Segarane, A Li, R Paudel, S Scholz, J Neumann, A Lees, T Revesz, J Hardy, C J Mathias, N W Wood, J Holton, H Houlden

Journal: Neurology. 2009 Mar;72(13):1185-6.

 

Last Updated: 31 Mar 2009

Go To URL
Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients.
 

Author(s): Hirohisa Watanabe, Yufuko Saito, Shinichi Terao, Tetsuo Ando, Teruhiko Kachi, Eiichiro Mukai, Ikuko Aiba, Yuji Abe, Akiko Tamakoshi, Manabu Doyu, Masaaki Hirayama, Gen Sobue

Journal: Brain. 2002 May;125(Pt 5):1070-83.

 

We investigated the disease progression and survival in 230 Japanese patients with multiple system atrophy (MSA; 131 men, 99 women; 208 probable MSA, 22 definite; mean age at onset, 55.4 years). Cerebellar dysfunction (multiple system atrophy-cerebellar; MSA-C) predominated in 155 ...

Last Updated: 18 Apr 2002

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)
 

Status: Recruiting

Condition Summary: Multiple System Atrophy - Parkinsonian Subtype (MSA-P); Multiple System Atrophy - Cerebellar Subtype (MSA-C)

 

Last Updated: 23 May 2014

Go to URL
Oligomeric Alpha-synuclein in Multiple System Atrophy
 

Status: Recruiting

Condition Summary: Multiple System Atrophy (MSA)

 

Last Updated: 9 May 2014

Go to URL
Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy
 

Status: Recruiting

Condition Summary: Multiple System Atrophy

 

Last Updated: 3 Jul 2014

Go to URL